S. Morris

473 total citations
13 papers, 267 citations indexed

About

S. Morris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, S. Morris has authored 13 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in S. Morris's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Morris is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Morris collaborates with scholars based in Switzerland, United States and Germany. S. Morris's co-authors include Martin Reck, Richard de Boer, Aaron S. Mansfield, Stephen V. Liu, Leora Horn, Marina Chiara Garassino, Raffaele Califano, Caroleen Quach, Xiaoming Wen and Sivuonthanh Lam and has published in prestigious journals such as International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology and European Journal of Cancer.

In The Last Decade

S. Morris

12 papers receiving 264 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Morris Switzerland 7 243 123 93 53 30 13 267
J.-S. Lee South Korea 7 268 1.1× 200 1.6× 44 0.5× 66 1.2× 22 0.7× 17 310
Yujia Chi China 11 110 0.5× 125 1.0× 39 0.4× 41 0.8× 21 0.7× 20 209
Masashi Kasajima Japan 11 246 1.0× 190 1.5× 52 0.6× 41 0.8× 13 0.4× 29 303
Jocelyn Booth United States 5 82 0.3× 62 0.5× 82 0.9× 53 1.0× 25 0.8× 11 156
Margaux Geier France 8 167 0.7× 150 1.2× 26 0.3× 23 0.4× 18 0.6× 41 220
M.E. Olmedo Spain 9 194 0.8× 121 1.0× 91 1.0× 111 2.1× 15 0.5× 24 282
Masafumi Sata Japan 10 202 0.8× 194 1.6× 20 0.2× 51 1.0× 20 0.7× 25 283
Patricia Rich United States 7 103 0.4× 39 0.3× 41 0.4× 54 1.0× 27 0.9× 19 159
J.R. Fischer Germany 9 247 1.0× 191 1.6× 75 0.8× 78 1.5× 13 0.4× 20 300
Francesca Ambrosio Italy 7 184 0.8× 73 0.6× 120 1.3× 98 1.8× 6 0.2× 13 265

Countries citing papers authored by S. Morris

Since Specialization
Citations

This map shows the geographic impact of S. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Morris more than expected).

Fields of papers citing papers by S. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Morris. The network helps show where S. Morris may publish in the future.

Co-authorship network of co-authors of S. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of S. Morris. A scholar is included among the top collaborators of S. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Morris. S. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Oertel, Markus F., Dennis Göerlich, S. Morris, et al.. (2024). Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma – First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology*Biology*Physics. 120(2). S65–S66. 1 indexed citations
2.
3.
4.
5.
Reck, Martin, Leora Horn, Tony Mok, et al.. (2021). OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S128–S128. 1 indexed citations
6.
Liu, Stephen V., Tony Mok, Aaron S. Mansfield, et al.. (2021). VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo). Annals of Oncology. 32(8). 1063–1065. 4 indexed citations
7.
Mansfield, Aaron S., Andrzej Każarnowicz, Nina Karaseva, et al.. (2020). Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Annals of Oncology. 31(2). 310–317. 126 indexed citations
8.
West, Howard, Federico Cappuzzo, Martin Reck, et al.. (2020). 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. Annals of Oncology. 31. S817–S818. 14 indexed citations
9.
Liu, Stephen V., Leora Horn, Tony Mok, et al.. (2020). 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer. Annals of Oncology. 31. S1032–S1033. 14 indexed citations
10.
McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations
11.
12.
Gandara, David R., Martin Reck, S. Morris, et al.. (2018). Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC. Annals of Oncology. 29. x39–x39. 21 indexed citations
13.
Blagden, Sarah P., Anne Hamilton, Linda Mileshkin, et al.. (2014). 3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. European Journal of Cancer. 50. 7–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.-S. Lee Breakdown of academic impact, for papers by Yujia Chi Breakdown of academic impact, for papers by Masashi Kasajima Breakdown of academic impact, for papers by Jocelyn Booth Breakdown of academic impact, for papers by Margaux Geier Breakdown of academic impact, for papers by M.E. Olmedo Breakdown of academic impact, for papers by Masafumi Sata Breakdown of academic impact, for papers by Patricia Rich Breakdown of academic impact, for papers by J.R. Fischer Breakdown of academic impact, for papers by Francesca Ambrosio
Rankless by CCL
2026